Grace Therapeutics (GRCE) EBT (2019 - 2026)

Grace Therapeutics has disclosed EBT across 8 years of filings, most recently posting -$15.8 million for Q2 2026.

• In Q2 2026, EBT fell 369.66% year-over-year to -$15.8 million; the TTM figure through Jun 2026 stood at -$21.9 million (down 71.42% YoY), while the FY2026 annual figure was -$9.5 million, up 25.64% from the prior year.
• EBT came in at -$15.8 million for Q2 2026 at Grace Therapeutics, down from -$2.9 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$382000.0 in Q1 2025 to a low of -$38.0 million in Q1 2023.
• Average EBT over 5 years is -$6.1 million, with a median of -$4.1 million recorded in 2022.
• Year-over-year, EBT plunged 733.88% in 2023 and soared 90.58% in 2025.
• Over 5 years, EBT stood at -$4.2 million in 2022, then surged by 37.57% to -$2.6 million in 2023, then sank by 83.15% to -$4.8 million in 2024, then soared by 51.37% to -$2.3 million in 2025, then tumbled by 582.07% to -$15.8 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$15.8 million in Q2 2026, -$2.9 million in Q1 2026, and -$2.3 million in Q4 2025.